Progressive Care (RXMD) 10-Q 13 Aug 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 09, 2024
Document Information [Line Items]
Entity Central Index Key	0001402945
Entity Registrant Name	Progressive Care Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	000-52684
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0186005
Entity Address, Address Line One	400 Ansin Blvd., Suite A
Entity Address, City or Town	Hallandale Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33009
City Area Code	305
Local Phone Number	760-2053
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,392,358

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current Assets
Cash	$ 8,537	$ 7,895
Accounts receivable – trade, net	9,391	8,339
Receivables - other, net	1,013	1,846
Inventory, net	2,343	3,069
Prepaid expenses	139	334
Total Current Assets	21,423	21,483
Property and equipment, net	3,157	3,284
Other Assets
Goodwill	0	731
Intangible assets, net	3,977	14,398
Operating right-of-use assets, net	213	427
Finance right-of-use assets, net	18	22
Deposits	39	39
Total Other Assets	4,247	15,617
Total Assets	28,827	40,384
Current Liabilities
Accounts payable and accrued liabilities	10,329	12,158
Notes payable	142	145
Operating lease liabilities	193	170
Finance lease liabilities	13	18
Total Current Liabilities	10,677	12,491
Long-term Liabilities
Notes payable, net of current portion	1,052	1,110
Operating lease liabilities, net of current portion	117	214
Finance lease liabilities, net of current portion	0	5
Total Liabilities	11,846	13,820
Commitments and Contingencies
Stockholders’ Equity
Common stock ($0.0001 par value, 100,000,000 shares authorized; 6,240,731 and 6,222,781 issued and outstanding as of June 30, 2024 and December 31, 2023, respectively)	67	67
Additional paid-in capital	60,951	60,886
Accumulated deficit	(44,037)	(34,389)
Total Stockholders’ Equity	16,981	26,564
Total Liabilities and Stockholders’ Equity	28,827	40,384
Series A Preferred Stock [Member]
Stockholders’ Equity
Preferred Stock	0	0
Series B Preferred Stock [Member]
Stockholders’ Equity
Preferred Stock	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Preferred stock, shares authorized (in shares)	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	6,240,731	6,222,781
Common stock, shares outstanding (in shares)	6,240,731	6,222,781
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	51	51
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	100,000	100,000
Preferred stock, shares issued (in shares)	3,000	3,000
Preferred stock, shares outstanding (in shares)	3,000	3,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2024		Jun. 30, 2023	Jun. 30, 2024		Jun. 30, 2023
Revenues, net	$ 13,477		$ 11,556	$ 28,105		$ 22,948
Costs of revenue	8,782		7,997	19,405		16,242
Gross profit	4,695		3,559	8,700		6,706
Operating expenses
Salaries and wages	2,166		1,701	4,282		3,300
Professional fees	384		274	862		1,048
Depreciation and amortization	757		72	1,533		137
Selling, general, and administrative	895		888	1,795		1,583
Impairment loss	9,792	[1]	0	9,924	[1]	0
Total operating expenses	13,994		2,935	18,396		6,068
(Loss) income from operations	(9,299)		624	(9,696)		638
Other income (expense):
Debt conversion expense	0		(5,206)	0		(5,206)
Gain on sale or disposal of property and equipment	0		3	1		3
Interest income	40		7	80		12
Interest expense	(17)		(65)	(33)		(214)
Total other income (expense)	23		(5,261)	48		(5,405)
Loss before income taxes	(9,276)		(4,637)	(9,648)		(4,767)
Provision for income taxes	0		0	0		0
Net loss attributable to common shareholders	$ (9,276)		$ (4,637)	$ (9,648)		$ (4,767)
Basic and diluted weighted average loss per common share (in dollars per share)	$ (1.49)		$ (1.05)	$ (1.55)		$ (1.22)
Weighted average number of common shares outstanding during the period – basic and diluted (in shares)	6,241		4,427	6,240		3,896
Product [Member]
Revenues, net	$ 10,518		$ 9,399	$ 21,773		$ 19,193
Costs of revenue	8,719		7,937	19,279		16,132
Service [Member]
Revenues, net	2,959		2,157	6,332		3,755
Costs of revenue	$ 63		$ 60	$ 126		$ 110
[1]Pharmacy Operations impairment loss during the six months ended June 30, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	0	3	3,347
Balance at Dec. 31, 2022	$ 0	$ 0	$ 67	$ 22,525	$ (14,974)	$ 7,618
Stock-based compensation (in shares)	0	0	11
Stock-based compensation	$ 0	$ 0	$ 0	50		50
Net income (loss)	$ 0	$ 0	$ 0	0	(130)	(130)
Balance (in shares) at Mar. 31, 2023	0	3	3,358
Balance at Mar. 31, 2023	$ 0	$ 0	$ 67	22,575	(15,104)	7,538
Balance (in shares) at Dec. 31, 2022	0	3	3,347
Balance at Dec. 31, 2022	$ 0	$ 0	$ 67	22,525	(14,974)	7,618
Net income (loss)						(4,767)
Balance (in shares) at Jun. 30, 2023	0	3	5,188
Balance at Jun. 30, 2023	$ 0	$ 0	$ 67	30,055	(19,741)	10,381
Balance (in shares) at Mar. 31, 2023	0	3	3,358
Balance at Mar. 31, 2023	$ 0	$ 0	$ 67	22,575	(15,104)	7,538
Stock-based compensation (in shares)	0	0	63
Stock-based compensation	$ 0	$ 0	$ 0	200		200
Net income (loss)	$ 0	$ 0	$ 0	0	(4,637)	(4,637)
Issuance of common stock for PIPE transaction (in shares)	0	0	455
Issuance of common stock for PIPE transaction	$ 0	$ 0	$ 0	1,000	0	1,000
Cost associated with issuance of common stock for PIPE transaction	$ 0	$ 0	$ 0	(120)	0	(120)
Issuance of common stock and common stock purchase warrants for debt conversion (in shares)	0	0	1,312
Issuance of common stock and common stock purchase warrants for debt conversion	$ 0	$ 0	$ 0	6,400	0	6,400
Balance (in shares) at Jun. 30, 2023	0	3	5,188
Balance at Jun. 30, 2023	$ 0	$ 0	$ 67	30,055	(19,741)	10,381
Balance (in shares) at Dec. 31, 2023	0	3	6,223
Balance at Dec. 31, 2023	$ 0	$ 0	$ 67	60,886	(34,389)	26,564
Stock-based compensation (in shares)	0	0	18
Stock-based compensation	$ 0	$ 0	$ 0	65		65
Net income (loss)	$ 0	$ 0	$ 0	0	(372)	(372)
Balance (in shares) at Mar. 31, 2024	0	3	6,241
Balance at Mar. 31, 2024	$ 0	$ 0	$ 67	60,951	(34,761)	26,257
Balance (in shares) at Dec. 31, 2023	0	3	6,223
Balance at Dec. 31, 2023	$ 0	$ 0	$ 67	60,886	(34,389)	26,564
Net income (loss)						(9,648)
Balance (in shares) at Jun. 30, 2024	0	3	6,241
Balance at Jun. 30, 2024	$ 0	$ 0	$ 67	60,951	(44,037)	16,981
Balance (in shares) at Mar. 31, 2024	0	3	6,241
Balance at Mar. 31, 2024	$ 0	$ 0	$ 67	60,951	(34,761)	26,257
Net income (loss)	$ 0	$ 0	$ 0	0	(9,276)	(9,276)
Balance (in shares) at Jun. 30, 2024	0	3	6,241
Balance at Jun. 30, 2024	$ 0	$ 0	$ 67	$ 60,951	$ (44,037)	$ 16,981

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024		Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (9,648,000)		$ (4,767,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	160,000		96,000
Change in provision for doubtful accounts	(54,000)		21,000
Amortization of debt issuance costs and debt discounts	0		128,000
Stock-based compensation	65,000		250,000
Debt conversion expense	0		5,206,000
Amortization of right-of-use assets - finance leases	13,000		17,000
Amortization of right-of-use assets - operating leases	73,000		78,000
Change in accrued interest on notes payable	0		47,000
Amortization of intangible assets	1,360,000		24,000
Gain on sale or disposal of property and equipment	(1,000)		(3,000)
Impairment loss	9,924,000	[1]	0
Changes in operating assets and liabilities:
Accounts receivable	(165,000)		(1,100,000)
Grant receivable	0		277,000
Inventory	726,000		(918,000)
Prepaid expenses	195,000		26,000
Deposits	0		(1,000)
Accounts payable and accrued liabilities	(1,769,000)		850,000
Operating lease liabilities	(71,000)		(81,000)
Net cash provided by operating activities	808,000		150,000
Cash flows from investing activities:
Purchase of property and equipment	(63,000)		(234,000)
Proceeds from sale or disposal of property and equipment	1,000		3,000
Net cash used in investing activities	(62,000)		(231,000)
Cash flows from financing activities:
Payments on notes payable	(91,000)		(173,000)
Payments on finance lease liabilities	(13,000)		(17,000)
Issuance of common stock for PIPE transaction	0		1,000,000
Payment of stock issuance costs	0		(120,000)
Net cash (used in) provided by financing activities	(104,000)		690,000
Increase in cash	642,000		609,000
Cash at beginning of period	7,895,000		6,743,000
Cash at end of period	8,537,000		7,352,000
Supplemental disclosures of cash flow information:
Cash paid for interest	17,000		37,000
Cash paid for income taxes	0		0
Supplemental schedule of non-cash investing and financing activities:
Debt conversion of long-term notes payable and accrued interest, net of unamortized debt discount and debt issuance costs	0		1,195,000
Issuance of common stock and common stock purchase warrants for debt conversion	$ 0		$ 6,400,000
[1]Pharmacy Operations impairment loss during the six months ended June 30, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.

Note 1 - Organization & Nature

Note 1 - Organization & Nature of Operations	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Nature of Operations [Text Block]	Note 1. Progressive Care Inc. (“Progressive”) was incorporated under the laws of the state of Delaware on October 31, 2006. Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901” 1002, 1002” 1103 1204 1103” 1204” Pharmco 901 November 29, 2005 901 October 21, 2010. 901 not Pharmco 1103 1103 June 1, 2019. Pharmco 1002 1002 July 1, 2018. ClearMetrX was formed on June 10, 2020 third 340B RXMD Therapeutics was formed on October 1, 2019. no We have organized our operations into two 15. On June 30, 2023, July 1, 2023, 805, Business Combinations July 1, 2023 June 30, 2023 July 1, 2023 On April 12, 2024, The Merger Agreement and the transactions contemplated thereby were negotiated and approved by a Special Committee comprised of three The Company’s shareholders will consider a proposal to approve the Merger at the Company’s annual meeting which is set to occur on September 13, 2024. July 29, 2024

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Principles of Consolidation	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Basis of Accounting [Text Block]	Note 2. The accompanying Unaudited Condensed Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) on a basis consistent with reporting interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements. Interim results are not may not 2023 10 The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Certain 2023 2024 not three six June 30, 2023. not

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3. The significant accounting policies of the Company were described in Note 3 10 December 31, 2023 no six June 30, 2024 Cash The Company maintains its cash in bank deposit accounts at several financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”) and at times may $250,000. June 30, 2024 July 2023, $250,000. Concentrations Suppliers: The Company had significant concentrations with one vendor. The purchases from this significant vendor were 98% and 97% of total vendor purchases for the six June 30, 2024 six June 30, 2023 Customers: The Company derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three Successor Predecessor Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 A 32 % 28 % B 22 % 1 % C 18 % 38 % Direct and Indirect Remuneration (“DIR”) Fees DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, not two two three September – December 2023 May – June 2024). December 31, 2023, not second 2024. January 1, 2024, Recently Adopted Accounting Standards None. Accounting Pronouncements Issued but not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, Q1 2025, December 31, 2024. not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not Subsequent Events The Company has evaluated subsequent events through August 13, 2024,

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4. Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three may Level 1: Level 2: 1 not Level 3: no The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments: ● Cash, accounts receivable, and accounts payable and accrued liabilities: ● Notes payable and lease liabilities: 2 Fair Value Measurement on a Nonrecurring Basis Common Stock Purchase Warrants As of June 30, 2024, 3 3.7%; 102%; 13.

Note 5 - Revenue

Note 5 - Revenue	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 5. The following table disaggregates net revenues by categories (in thousands): Successor Predecessor Three Months Ended June 30, 2024 Three Months Ended June 30, 2023 Sales of products, net Prescription revenue, net of PBM fees $ 10,521 $ 9,448 COVID-19 testing revenue — 8 Other revenue — 6 Subtotal 10,521 9,462 Revenues from services: 340B contract revenue 2,956 2,094 Revenues, net $ 13,477 $ 11,556 Successor Predecessor Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 Sales of products, net Prescription revenue, net of PBM fees $ 21,845 $ 19,219 COVID-19 testing revenue — 54 Other revenue — 5 Subtotal 21,845 19,278 Revenues from services: 340B contract revenue 6,260 3,670 Revenues, net $ 28,105 $ 22,948

Note 6 - Earnings (Loss) Per Sh

Note 6 - Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 6. Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted earnings per share gives effect to all potentially dilutive shares of common stock outstanding during the period including common stock purchase warrants and stock options, using the treasury stock method, and convertible debt, using the if converted method. Diluted earnings per share excludes all dilutive potential of shares of common stock if their effect is anti-dilutive. The components of basic and diluted EPS were as follows (in thousands, except per share data). For all periods presented, the Company incurred a net loss causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in diluted loss per common share and basic loss per common share being equivalent. Successor Predecessor Three Months Ended June 30, 2024 Three Months Ended June 30, 2023 Net loss attributable to common shareholders $ (9,276 ) $ (4,637 ) Basic weighted average common shares outstanding 6,241 4,427 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 6,241 4,427 Basic weighted average loss per common share $ (1.49 ) $ (1.05 ) Diluted weighted average loss per common share $ (1.49 ) $ (1.05 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Common stock purchase warrants 2,367 2,774 Stock options 323 156 2,690 2,930 Successor Predecessor Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 Net loss attributable to common shareholders $ (9,648 ) $ (4,767 ) Basic weighted average common shares outstanding 6,240 3,896 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 6,240 3,896 Basic weighted average loss per common share $ (1.55 ) $ (1.22 ) Diluted weighted average loss per common share $ (1.55 ) $ (1.22 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Common stock purchase warrants 1,910 1,155 Stock options 57 176 1,967 1,331

Note 7 - Accounts Receivable -

Note 7 - Accounts Receivable - Trade, Net	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 7. Trade, net Accounts receivable consisted of the following (in thousands): Successor June 30, 2024 December 31, 2023 Gross accounts receivable – trade $ 9,609 $ 8,611 Less: allowance for credit losses (218 ) (272 ) Accounts receivable – trade, net $ 9,391 $ 8,339 The Successor Company decreased the allowance for credit losses in the amount of approximately $56,000 and $54,000 for the three six June 30, 2024 three six June 30, 2023 Accounts receivable – trade, net for the Predecessor Company as of January 1, 2023 June 30, 2023

Note 8 - Receivables - Other, n

Note 8 - Receivables - Other, net	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	Note 8. Receivables – Other, net consisted of the following (in thousands): Successor June 30, 2024 December 31, 2023 Performance bonuses $ 792 $ 1,602 Customers 188 192 Other 33 52 $ 1,013 $ 1,846 Performance bonuses, paid annually by PBMs, are estimated (accrued monthly) based on historical pharmacy performance and prior payments received. Other receivables are comprised of vendor credits and loans to employees.

Note 9 - Property and Equipment

Note 9 - Property and Equipment, Net	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 9. Property and equipment, net consisted of the following (in thousands): Successor Estimated Useful Life June 30, 2024 December 31, 2023 Building 40 years $ 2,116 $ 2,116 Vehicles 3 - 5 years 603 595 Furniture and equipment 5 years 388 388 Land --- 184 184 Leasehold improvements and fixtures Lesser of estimated useful life or life of lease 119 76 Computer equipment 3 years 39 39 Construction in progress --- — 22 Total 3,449 3,420 Less: accumulated depreciation (292 ) (136 ) Property and equipment, net $ 3,157 $ 3,284 Depreciation expense for the Successor Company was approximately $0.1 million and $0.2 million for the three six June 30, 2024 three six June 30, 2023

Note 10 - Goodwill and Intangib

Note 10 - Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 10. Goodwill During the three June 30, 2024, With the assistance of a third 3 The changes in the carrying amount of goodwill by reporting segment during the six June 30, 2024 Pharmacy Operations Third-Party Administration Total Balance at December 31, 2023 $ — $ 731 $ 731 Goodwill impairment loss — (731 ) (731 ) Balance at June 30, 2024 $ — $ — $ — Intangible Assets During the three June 30, 2024, not not third 3 three June 30, 2024 ( four no The following table provides the gross carrying amount, accumulated amortization, and net book value for each major class of intangible assets (in thousands): Successor June 30, 2024 December 31, 2023 Gross amount Accumulated amortization Net Amount Gross amount Accumulated amortization Net Amount Pharmacy records $ 2,447 $ — $ 2,447 $ 8,130 $ (807 ) $ 7,323 Tradenames 1,530 — 1,530 4,700 (224 ) 4,476 Developed technology — — — 2,880 (281 ) 2,599 Total intangible assets $ 3,977 $ — $ 3,977 $ 15,710 $ (1,312 ) $ 14,398 A summary of the changes to the gross carrying amount, accumulated amortization, and net book value of total intangible assets by reporting unit during the six June 30, 2024 Pharmacy Operations Third-Party Administration Total Balances at December 31, 2023: Gross amount $ 12,650 $ 3,060 $ 15,710 Accumulated amortization (1,023 ) (289 ) (1,312 ) Net amount 11,627 2,771 14,398 Changes during the six months ended June 30, 2024: Accumulated amortization expense (1,055 ) (305 ) (1,360 ) Impairment - gross amount (8,673 ) (3,060 ) (11,733 ) Impairment - accumulated amortization 2,078 594 2,672 Net amount (7,650 ) (2,771 ) (10,421 ) Balances at June 30, 2024: Gross amount 3,977 — 3,977 Accumulated amortization — — — Net amount $ 3,977 $ — $ 3,977 Amortization expense of intangible assets for the Successor Company was approximately $0.7 million and $1.4 million for the three six June 30, 2024 three six June 30, 2023 The following table represents the total estimated future amortization of intangible assets for the five June 30, 2024 Successor Year Amount 2024 (remaining six months) $ 497 2025 994 2026 994 2027 994 2028 498 Thereafter — Total $ 3,977

Note 11 - Accounts Payable and

Note 11 - Accounts Payable and Accrued Liabilities	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 11. Accounts payable and accrued liabilities consisted of the following (in thousands): Successor June 30, 2024 December 31, 2023 Accounts payable – trade $ 10,046 $ 11,256 Accrued payroll and payroll taxes 181 167 Accrued PBM fees — 571 Other accrued liabilities 102 164 Total $ 10,329 $ 12,158

Note 12 - Notes Payable

Note 12 - Notes Payable	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 12. Notes payable consisted of the following (in thousands): Successor June 30, 2024 December 31, 2023 A. Mortgage note payable - commercial bank - collateralized $ 1,096 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 73 90 Subtotal 1,194 1,255 Less: current portion of notes payable (142 ) (145 ) Long-term portion of notes payable $ 1,052 $ 1,110 The corresponding notes payable above are more fully discussed below: (A) Mortgage Note Payable – collateralized In 2018, 901 400 December 14, 2028 119 January 2019, not December 14, 2028. (B) Note Payable – Uncollateralized As of June 30, 2024 December 31, 2023 (C) Notes Payable – Collateralized In April 2021, September 2021, 46 June 30, 2024 December 31, 2023 In July 2022, 60 January 2023. June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 In September 2022, 24 October 2022. June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 Principal outstanding as of June 30, 2024 Successor Year Amount 2024 (remaining six months) $ 84 2025 114 2026 119 2027 124 2028 753 Total $ 1,194 Interest expense on these notes payable for the Successor Company was approximately $14,000 and $28,000 for the three six June 30, 2024 three six June 30, 2023

Note 13 - Stockholders' Equity

Note 13 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Equity [Text Block]	Note 13. Equity Preferred Stock The Company has 10,000,000 shares of preferred stock authorized. As of June 30, 2024 December 31, 2023 Series A Preferred Stock - Predecessor Company The Series A preferred stock is a non-dividend producing instrument that ranks superior to the Company’s common stock. Each one 1 x 0.019607 multiplied by divided by 0.49, minus With respect to all matters upon which stockholders are entitled to vote or to which shareholders are entitled to give consent, the holders of the outstanding shares of Series A Preferred Stock shall vote together with the holders of common stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws. In July 2014, October 2020, August 2022, Series B Convertible Preferred Stock - Predecessor Company On August 30, 2022, one one may The Series B Convertible Preferred Stock ranks senior to our common stock as to distribution of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary. The shares of Series B Convertible Preferred Stock shall have a liquidation preference to all other classes of stock of the Company in the amount of $2,000 per share. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Series B Convertible Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company (i) $2,000 per share plus (ii) the same amount that a holder of common stock would receive if the Series B Convertible Preferred Stock were fully converted to common stock which amounts shall be paid pari passu With respect to all matters upon which stockholders are entitled to vote or to which shareholders are entitled to give consent, the holders of the outstanding shares of Preferred Stock shall vote together with the holders of common stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws. Common Stock and Common Stock Purchase Warrants On May 5, 2023, three 480 July 1, 2023, Also on May 5, 2023, September 2, 2022, three 480 July 1, 2023, June 30, 2024 At the same time as the SPA and DCA, the Predecessor Company and NextPlat entered into the Debenture Purchase Agreement. Under the Debenture Purchase Agreement, the Predecessor Company agreed to issue, and NextPlat agreed to purchase, from time to time during the three June 30, 2024 Dawson James Securities, Inc. (the “Placement Agent”) served as placement agent for the Unit Purchase. In consideration for the Placement Agent’s services, the Predecessor Company issued to the Placement Agent and its affiliates warrants to purchase 91,000 shares of Common Stock (the “Placement Agent Warrants”). The Placement Agent Warrants have a five December 2023. 480 In addition, the Predecessor Company issued 330,000 warrants to certain existing Progressive Care investors to induce them to approve the transaction contemplated by the SPA (the “Inducement Warrants”). Charles M. Fernandez and Rodney Barreto received Inducement Warrants to purchase 190,000 and 30,000 shares of Common Stock, respectively. The Inducement Warrants have a three 480 July 1, 2023, June 30, 2024

Note 14 - Stock-based Compensat

Note 14 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 14. Stock-based compensation is recorded in selling, general, and administrative expenses in the Unaudited Condensed Consolidated Statement of Operations. The Successor Company recorded total stock-based compensation expense of approximately $65,000 for the six June 30, 2024; three June 30, 2024. three six June 30, 2023.

Note 15 - Reportable Segments

Note 15 - Reportable Segments	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 15. The Company has two 19 340B 340B Corporate includes certain assets and expenses related to corporate functions that are not The Company evaluates the performance of each of the segments based on income (loss) from operations. While the Company believes there are synergies between the two The accounting policies used to determine the results of the operating segments are the same as those utilized for the Consolidated Financial Statements as a whole. There are no The following tables present a summary of net income (loss) of the reportable segments (in thousands): Successor Three Months Ended June 30, 2024 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 10,518 $ — $ — $ 10,518 Revenues from services 2,649 310 — 2,959 Revenues, net 13,167 310 — 13,477 Costs of products 8,719 — — 8,719 Costs of services — 63 — 63 Costs of revenue 8,719 63 — 8,782 Gross profit 4,448 247 — 4,695 Operating expenses: Salaries and wages 1,958 34 174 2,166 Professional fees 25 45 314 384 Depreciation and amortization 604 149 4 757 Selling, general, and administrative 747 5 143 895 Impairment loss 6,595 3,197 — 9,792 Total operating expenses 9,929 3,430 635 13,994 Loss from operations (5,481 ) (3,183 ) (635 ) (9,299 ) Other (expense) income (15 ) — 38 23 Loss before income taxes (5,496 ) (3,183 ) (597 ) (9,276 ) Provision for income taxes — — — — Net loss $ (5,496 ) $ (3,183 ) $ (597 ) $ (9,276 ) Predecessor Three Months Ended June 30, 2023 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 9,399 $ — $ — $ 9,399 Revenues from services 1,477 680 — 2,157 Revenues, net 10,876 680 — 11,556 Costs of products 7,937 — — 7,937 Costs of services — 60 — 60 Costs of revenue 7,937 60 — 7,997 Gross profit 2,939 620 — 3,559 Operating expenses: Salaries and wages 1,527 20 154 1,701 Professional fees 6 60 208 274 Depreciation and amortization 63 4 5 72 Selling, general, and administrative 638 4 246 888 Total operating expenses 2,234 88 613 2,935 Loss from operations 705 532 (613 ) 624 Other expense (15 ) — (5,246 ) (5,261 ) Income (loss) before income taxes 690 532 (5,859 ) (4,637 ) Provision for income taxes — — — — Net income (loss) $ 690 $ 532 $ (5,859 ) $ (4,637 ) Successor Six Months Ended June 30, 2024 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 21,773 $ — $ — $ 21,773 Revenues from services 5,489 843 — 6,332 Revenues, net 27,262 843 — 28,105 Costs of products 19,279 — — 19,279 Costs of services — 126 — 126 Costs of revenue 19,279 126 — 19,405 Gross profit 7,983 717 — 8,700 Operating expenses: Salaries and wages 3,859 67 356 4,282 Professional fees 29 126 707 862 Depreciation and amortization 1,219 305 9 1,533 Selling, general, and administrative 1,517 12 266 1,795 Impairment loss 6,727 3,197 — 9,924 Total operating expenses 13,351 3,707 1,338 18,396 Loss from operations (5,368 ) (2,990 ) (1,338 ) (9,696 ) Other (expense) income (30 ) — 78 48 Loss before income taxes (5,398 ) (2,990 ) (1,260 ) (9,648 ) Provision for income taxes — — — — Net loss $ (5,398 ) $ (2,990 ) $ (1,260 ) $ (9,648 ) Predecessor Six Months Ended June 30, 2023 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 19,193 $ — $ — $ 19,193 Revenues from services 2,558 1,197 — 3,755 Revenues, net 21,751 1,197 — 22,948 Costs of products 16,132 — — 16,132 Costs of services — 110 — 110 Costs of revenue 16,132 110 — 16,242 Gross profit 5,619 1,087 — 6,706 Operating expenses: Salaries and wages 2,972 52 276 3,300 Professional fees 389 156 503 1,048 Depreciation and amortization 123 9 5 137 Selling, general, and administrative 1,226 8 349 1,583 Total operating expenses 4,710 225 1,133 6,068 Income (loss) from operations 909 862 (1,133 ) 638 Other expense (27 ) — (5,378 ) (5,405 ) Income (loss) before income taxes 882 862 (6,511 ) (4,767 ) Provision for income taxes — — — — Net income (loss) $ 882 $ 862 $ (6,511 ) $ (4,767 ) Pharmacy Operations Third-Party Administration Corporate Eliminations (1) Total Consolidated Total Assets as of June 30, 2024 (Successor) $ 29,900 $ 1,701 $ — $ (2,774 ) $ 28,827 Total Assets as of December 31, 2023 (Successor) $ 38,516 $ 4,573 $ 69 $ (2,774 ) $ 40,384 ( 1 Capital expenditures for the Pharmacy Operations reporting segment were approximately $18,000 and $0.1 million for the three six June 30, 2024 three six June 30, 2023 no three six June 30, 2024 three six June 30, 2023

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 16. Successor Company During the three six June 30, 2024, May 1, 2023. Predecessor Company On May 5, 2023, On May 9, 2023, On February 1, 2023, May 1, 2023, three six June 30, 2023,

Note 17 - Commitments and Conti

Note 17 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 17. On June 17, 2024,

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		5. OTHER INFORMATION Rule 10b5 1 During the three June 30, 2024 no 10b5 1 10b5 1 408
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company maintains its cash in bank deposit accounts at several financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”) and at times may $250,000. June 30, 2024 July 2023, $250,000.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Customers: The Company derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three Successor Predecessor Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 A 32 % 28 % B 22 % 1 % C 18 % 38 %
Renumeration Fees [Policy Text Block]	Direct and Indirect Remuneration (“DIR”) Fees DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, not two two three September – December 2023 May – June 2024). December 31, 2023, not second 2024. January 1, 2024,
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards None. Accounting Pronouncements Issued but not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, Q1 2025, December 31, 2024. not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company has evaluated subsequent events through August 13, 2024,

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Successor Predecessor Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 A 32 % 28 % B 22 % 1 % C 18 % 38 %

Note 5 - Revenue (Tables)

Note 5 - Revenue (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Successor Predecessor Three Months Ended June 30, 2024 Three Months Ended June 30, 2023 Sales of products, net Prescription revenue, net of PBM fees $ 10,521 $ 9,448 COVID-19 testing revenue — 8 Other revenue — 6 Subtotal 10,521 9,462 Revenues from services: 340B contract revenue 2,956 2,094 Revenues, net $ 13,477 $ 11,556 Successor Predecessor Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 Sales of products, net Prescription revenue, net of PBM fees $ 21,845 $ 19,219 COVID-19 testing revenue — 54 Other revenue — 5 Subtotal 21,845 19,278 Revenues from services: 340B contract revenue 6,260 3,670 Revenues, net $ 28,105 $ 22,948

Note 6 - Earnings (Loss) Per _2

Note 6 - Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Successor Predecessor Three Months Ended June 30, 2024 Three Months Ended June 30, 2023 Net loss attributable to common shareholders $ (9,276 ) $ (4,637 ) Basic weighted average common shares outstanding 6,241 4,427 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 6,241 4,427 Basic weighted average loss per common share $ (1.49 ) $ (1.05 ) Diluted weighted average loss per common share $ (1.49 ) $ (1.05 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Common stock purchase warrants 2,367 2,774 Stock options 323 156 2,690 2,930 Successor Predecessor Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 Net loss attributable to common shareholders $ (9,648 ) $ (4,767 ) Basic weighted average common shares outstanding 6,240 3,896 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 6,240 3,896 Basic weighted average loss per common share $ (1.55 ) $ (1.22 ) Diluted weighted average loss per common share $ (1.55 ) $ (1.22 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Common stock purchase warrants 1,910 1,155 Stock options 57 176 1,967 1,331

Note 7 - Accounts Receivable _2

Note 7 - Accounts Receivable - Trade, Net (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	Successor June 30, 2024 December 31, 2023 Gross accounts receivable – trade $ 9,609 $ 8,611 Less: allowance for credit losses (218 ) (272 ) Accounts receivable – trade, net $ 9,391 $ 8,339

Note 8 - Receivables - Other,_2

Note 8 - Receivables - Other, net (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Other Receivables, Net [Table Text Block]	Successor June 30, 2024 December 31, 2023 Performance bonuses $ 792 $ 1,602 Customers 188 192 Other 33 52 $ 1,013 $ 1,846

Note 9 - Property and Equipme_2

Note 9 - Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	Successor Estimated Useful Life June 30, 2024 December 31, 2023 Building 40 years $ 2,116 $ 2,116 Vehicles 3 - 5 years 603 595 Furniture and equipment 5 years 388 388 Land --- 184 184 Leasehold improvements and fixtures Lesser of estimated useful life or life of lease 119 76 Computer equipment 3 years 39 39 Construction in progress --- — 22 Total 3,449 3,420 Less: accumulated depreciation (292 ) (136 ) Property and equipment, net $ 3,157 $ 3,284

Note 10 - Goodwill and Intang_2

Note 10 - Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Goodwill [Table Text Block]	Pharmacy Operations Third-Party Administration Total Balance at December 31, 2023 $ — $ 731 $ 731 Goodwill impairment loss — (731 ) (731 ) Balance at June 30, 2024 $ — $ — $ —
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Successor June 30, 2024 December 31, 2023 Gross amount Accumulated amortization Net Amount Gross amount Accumulated amortization Net Amount Pharmacy records $ 2,447 $ — $ 2,447 $ 8,130 $ (807 ) $ 7,323 Tradenames 1,530 — 1,530 4,700 (224 ) 4,476 Developed technology — — — 2,880 (281 ) 2,599 Total intangible assets $ 3,977 $ — $ 3,977 $ 15,710 $ (1,312 ) $ 14,398
Schedule of Intangible Assets and Goodwill [Table Text Block]	Pharmacy Operations Third-Party Administration Total Balances at December 31, 2023: Gross amount $ 12,650 $ 3,060 $ 15,710 Accumulated amortization (1,023 ) (289 ) (1,312 ) Net amount 11,627 2,771 14,398 Changes during the six months ended June 30, 2024: Accumulated amortization expense (1,055 ) (305 ) (1,360 ) Impairment - gross amount (8,673 ) (3,060 ) (11,733 ) Impairment - accumulated amortization 2,078 594 2,672 Net amount (7,650 ) (2,771 ) (10,421 ) Balances at June 30, 2024: Gross amount 3,977 — 3,977 Accumulated amortization — — — Net amount $ 3,977 $ — $ 3,977
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Successor Year Amount 2024 (remaining six months) $ 497 2025 994 2026 994 2027 994 2028 498 Thereafter — Total $ 3,977

Note 11 - Accounts Payable an_2

Note 11 - Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Successor June 30, 2024 December 31, 2023 Accounts payable – trade $ 10,046 $ 11,256 Accrued payroll and payroll taxes 181 167 Accrued PBM fees — 571 Other accrued liabilities 102 164 Total $ 10,329 $ 12,158

Note 12 - Notes Payable (Tables

Note 12 - Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Debt [Table Text Block]	Successor June 30, 2024 December 31, 2023 A. Mortgage note payable - commercial bank - collateralized $ 1,096 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 73 90 Subtotal 1,194 1,255 Less: current portion of notes payable (142 ) (145 ) Long-term portion of notes payable $ 1,052 $ 1,110
Schedule of Maturities of Long-Term Debt [Table Text Block]	Successor Year Amount 2024 (remaining six months) $ 84 2025 114 2026 119 2027 124 2028 753 Total $ 1,194

Note 15 - Reportable Segments (

Note 15 - Reportable Segments (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Successor Three Months Ended June 30, 2024 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 10,518 $ — $ — $ 10,518 Revenues from services 2,649 310 — 2,959 Revenues, net 13,167 310 — 13,477 Costs of products 8,719 — — 8,719 Costs of services — 63 — 63 Costs of revenue 8,719 63 — 8,782 Gross profit 4,448 247 — 4,695 Operating expenses: Salaries and wages 1,958 34 174 2,166 Professional fees 25 45 314 384 Depreciation and amortization 604 149 4 757 Selling, general, and administrative 747 5 143 895 Impairment loss 6,595 3,197 — 9,792 Total operating expenses 9,929 3,430 635 13,994 Loss from operations (5,481 ) (3,183 ) (635 ) (9,299 ) Other (expense) income (15 ) — 38 23 Loss before income taxes (5,496 ) (3,183 ) (597 ) (9,276 ) Provision for income taxes — — — — Net loss $ (5,496 ) $ (3,183 ) $ (597 ) $ (9,276 ) Predecessor Three Months Ended June 30, 2023 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 9,399 $ — $ — $ 9,399 Revenues from services 1,477 680 — 2,157 Revenues, net 10,876 680 — 11,556 Costs of products 7,937 — — 7,937 Costs of services — 60 — 60 Costs of revenue 7,937 60 — 7,997 Gross profit 2,939 620 — 3,559 Operating expenses: Salaries and wages 1,527 20 154 1,701 Professional fees 6 60 208 274 Depreciation and amortization 63 4 5 72 Selling, general, and administrative 638 4 246 888 Total operating expenses 2,234 88 613 2,935 Loss from operations 705 532 (613 ) 624 Other expense (15 ) — (5,246 ) (5,261 ) Income (loss) before income taxes 690 532 (5,859 ) (4,637 ) Provision for income taxes — — — — Net income (loss) $ 690 $ 532 $ (5,859 ) $ (4,637 ) Successor Six Months Ended June 30, 2024 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 21,773 $ — $ — $ 21,773 Revenues from services 5,489 843 — 6,332 Revenues, net 27,262 843 — 28,105 Costs of products 19,279 — — 19,279 Costs of services — 126 — 126 Costs of revenue 19,279 126 — 19,405 Gross profit 7,983 717 — 8,700 Operating expenses: Salaries and wages 3,859 67 356 4,282 Professional fees 29 126 707 862 Depreciation and amortization 1,219 305 9 1,533 Selling, general, and administrative 1,517 12 266 1,795 Impairment loss 6,727 3,197 — 9,924 Total operating expenses 13,351 3,707 1,338 18,396 Loss from operations (5,368 ) (2,990 ) (1,338 ) (9,696 ) Other (expense) income (30 ) — 78 48 Loss before income taxes (5,398 ) (2,990 ) (1,260 ) (9,648 ) Provision for income taxes — — — — Net loss $ (5,398 ) $ (2,990 ) $ (1,260 ) $ (9,648 ) Predecessor Six Months Ended June 30, 2023 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 19,193 $ — $ — $ 19,193 Revenues from services 2,558 1,197 — 3,755 Revenues, net 21,751 1,197 — 22,948 Costs of products 16,132 — — 16,132 Costs of services — 110 — 110 Costs of revenue 16,132 110 — 16,242 Gross profit 5,619 1,087 — 6,706 Operating expenses: Salaries and wages 2,972 52 276 3,300 Professional fees 389 156 503 1,048 Depreciation and amortization 123 9 5 137 Selling, general, and administrative 1,226 8 349 1,583 Total operating expenses 4,710 225 1,133 6,068 Income (loss) from operations 909 862 (1,133 ) 638 Other expense (27 ) — (5,378 ) (5,405 ) Income (loss) before income taxes 882 862 (6,511 ) (4,767 ) Provision for income taxes — — — — Net income (loss) $ 882 $ 862 $ (6,511 ) $ (4,767 )
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	Pharmacy Operations Third-Party Administration Corporate Eliminations (1) Total Consolidated Total Assets as of June 30, 2024 (Successor) $ 29,900 $ 1,701 $ — $ (2,774 ) $ 28,827 Total Assets as of December 31, 2023 (Successor) $ 38,516 $ 4,573 $ 69 $ (2,774 ) $ 40,384

Note 1 - Organization & Natur_2

Note 1 - Organization & Nature of Operations (Details Textual)		6 Months Ended
	Jul. 01, 2023 shares	Jun. 30, 2024	Oct. 21, 2010
Number of Reportable Segments		2
NextPlat Corp. and Messrs [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)	632,269
Fernandez [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)	211,470
Barreto [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)	130,571
NextPlat, Chief Executive Officer, and Board Director [Member]
Ownership Percentage	53%
Pharmco LLC [Member]
Subsidiary, Ownership Percentage, Parent			100%

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Textual) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023
Cash, Uninsured Amount	$ 3.5
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member]
Number of Major Vendors	1
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member] | One Vendor [Member]
Concentration Risk, Percentage	98%	97%

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Policies - Trade, Net - Concentrations (Details) - Customer Concentration Risk [Member] - Accounts Receivable [Member]	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Pharmacy Benefit Managers A [Member]
Concentration	32%	28%
Pharmacy Benefit Managers B [Member]
Concentration	22%	1%
Pharmacy Benefit Managers C [Member]
Concentration	18%	38%

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Details Textual) - Common Stock Purchase Warrants [Member] $ / shares in Units, $ in Millions	Jun. 30, 2024 USD ($) $ / shares
Warrants and Rights Outstanding | $	$ 4.6
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 2.2
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.035
Minimum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	3
Minimum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.93
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.037
Maximum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.6
Maximum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	1.02

Note 5 - Revenue - Disaggregati

Note 5 - Revenue - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 13,477	$ 11,556	$ 28,105	$ 22,948
Prescription [Member]
Revenue	10,521	9,448	21,845	19,219
COVID-19 Testing [Member]
Revenue	0	8	0	54
Rent and Other [Member]
Revenue	0	6	0	5
Product [Member]
Revenue	10,521	9,462	21,845	19,278
Three Hundred Forty B Contract [Member]
Revenue	$ 2,956	$ 2,094	$ 6,260	$ 3,670

Note 6 - Earnings (Loss) Per _3

Note 6 - Earnings (Loss) Per Share - Components of Basic and Dilutes Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net loss attributable to common shareholders	$ (9,276)	$ (4,637)	$ (9,648)	$ (4,767)
Weighted average number of common shares outstanding during the period – basic and diluted (in shares)	6,241	4,427	6,240	3,896
Potentially dilutive common shares (in shares)	0	0	0	0
Diluted weighted average common shares outstanding (in shares)	6,241	4,427	6,240	3,896
Basic and diluted weighted average loss per common share (in dollars per share)	$ (1.49)	$ (1.05)	$ (1.55)	$ (1.22)
Diluted weighted average loss per common share (in dollars per share)	$ (1.49)	$ (1.05)	$ (1.55)	$ (1.22)
Antidilutive securities (in shares)	2,690	2,930	1,967	1,331
Warrant [Member]
Antidilutive securities (in shares)	2,367	2,774	1,910	1,155
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	323	156	57	176

Note 7 - Accounts Receivable _3

Note 7 - Accounts Receivable - Trade, Net (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jan. 01, 2023
Accounts Receivable, Credit Loss Expense (Reversal)	$ (56,000)	$ 12,000	$ (54,000)	$ 21,000
Accounts Receivable, after Allowance for Credit Loss		$ 5,000,000		$ 5,000,000	$ 3,700,000

Note 7 - Accounts Receivable _4

Note 7 - Accounts Receivable - Trade, Net - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Gross accounts receivable – trade	$ 9,609	$ 8,611
Less: allowance for credit losses	(218)	(272)
Accounts receivable – trade, net	$ 9,391	$ 8,339

Note 8 - Receivables - Other,_3

Note 8 - Receivables - Other, Net - Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Performance bonuses	$ 792	$ 1,602
Customers	188	192
Other	33	52
Other Receivables, Net, Current	$ 1,013	$ 1,846

Note 9 - Property and Equipme_3

Note 9 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Depreciation			$ 160	$ 96
Depreciation Approximation [Member]
Depreciation	$ 100	$ 100	$ 200	$ 100

Note 9 - Property and Equipme_4

Note 9 - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property and equipment, gross	$ 3,449	$ 3,420
Less: accumulated depreciation	(292)	(136)
Property and equipment, net	$ 3,157	3,284
Building [Member]
Property, Plant and Equipment, Useful Life (Year)	40 years
Property and equipment, gross	$ 2,116	2,116
Vehicles [Member]
Property and equipment, gross	$ 603	595
Vehicles [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Vehicles [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Property and equipment, gross	$ 388	388
Land [Member]
Property and equipment, gross	184	184
Leasehold Improvements [Member]
Property and equipment, gross	$ 119	76
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Property and equipment, gross	$ 39	39
Construction in Progress [Member]
Property and equipment, gross	$ 0	$ 22

Note 10 - Goodwill and Intang_3

Note 10 - Goodwill and Intangible Assets (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2024
Goodwill, Impairment Loss			$ 731,000
Impairment of Intangible Assets (Excluding Goodwill)	$ 9,100,000		10,421,000
Intangible Assets, Net (Including Goodwill)	$ 3,977,000		3,977,000
Amortization of Intangible Assets			$ 1,360,000	$ 24,000
Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years		5 years		10 years
Pharmacy Records [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years		5 years
Amortization Approximation [Member]
Amortization of Intangible Assets	$ 700,000	$ 12,000	$ 1,400,000	$ 24,000
TPA Reporting Segment [Member]
Goodwill, Impairment Loss	700,000
Impairment of Intangible Assets (Excluding Goodwill)	$ 2,500,000
TPA Reporting Segment [Member] | Valuation, Income Approach [Member] | Measurement Input, Long-Term Revenue Growth Rate [Member]
Goodwill, Measurement Input	0.03		0.03
TPA Reporting Segment [Member] | Valuation, Income Approach [Member] | Measurement Input, Weighted Average Cost of Capital Used [Member]
Goodwill, Measurement Input	0.135		0.135
Pharmacy Operations [Member]
Goodwill, Impairment Loss			$ 0
Impairment of Intangible Assets (Excluding Goodwill)	$ 6,600,000		7,650,000
Intangible Assets, Net (Including Goodwill)	$ 3,977,000		3,977,000
Amortization of Intangible Assets			$ 1,055,000

Note 10 - Goodwill and Intang_4

Note 10 - Goodwill and Intangible Assets - Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Balance at December 31, 2023	$ 731
Goodwill impairment loss	(731)
Balance at June 30, 2024	0
Pharmacy Operations [Member]
Balance at December 31, 2023	0
Goodwill impairment loss	0
Balance at June 30, 2024	0
Third-party Administration [Member]
Balance at December 31, 2023	731
Goodwill impairment loss	(731)
Balance at June 30, 2024	$ 0

Note 10 - Goodwill and Intang_5

Note 10 - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Gross intangible assets	$ 3,977	$ 15,710
Accumulated amortization	0	(1,312)
Net intangible assets	3,977	14,398
Pharmacy Records [Member]
Gross intangible assets	2,447	8,130
Accumulated amortization	0	(807)
Net intangible assets	2,447	7,323
Trade Names [Member]
Gross intangible assets	1,530	4,700
Accumulated amortization	0	(224)
Net intangible assets	1,530	4,476
Developed Technology Rights [Member]
Gross intangible assets	0	2,880
Accumulated amortization	0	(281)
Net intangible assets	$ 0	$ 2,599

Note 10 - Goodwill and Intang_6

Note 10 - Goodwill and Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
Gross amount		$ 15,710
Accumulated amortization		(1,312)
Net amount		14,398
Accumulated amortization expense		(1,360)	$ (24)
Impairment - gross amount		(11,733)
Impairment - accumulated amortization		2,672
Net amount	$ (9,100)	(10,421)
Gross amount	3,977	3,977
Accumulated amortization	0	0
Net amount	3,977	3,977
Pharmacy Operations [Member]
Gross amount		12,650
Accumulated amortization		(1,023)
Net amount		11,627
Accumulated amortization expense		(1,055)
Impairment - gross amount		(8,673)
Impairment - accumulated amortization		2,078
Net amount	(6,600)	(7,650)
Gross amount	3,977	3,977
Accumulated amortization	0	0
Net amount	3,977	3,977
Third-party Administration [Member]
Gross amount		3,060
Accumulated amortization		(289)
Net amount		2,771
Accumulated amortization expense		(305)
Impairment - gross amount		(3,060)
Impairment - accumulated amortization		594
Net amount		(2,771)
Gross amount	0	0
Accumulated amortization	0	0
Net amount	$ 0	$ 0

Note 10 - Goodwill and Intang_7

Note 10 - Goodwill and Intangible Assets - Estimated Future Amortization of intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
2024 (remaining six months)	$ 497
2025	994
2026	994
2027	994
2028	498
Thereafter	0
Total	$ 3,977	$ 14,398

Note 11 - Accounts Payable an_3

Note 11 - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accounts payable – trade	$ 10,046	$ 11,256
Accrued payroll and payroll taxes	181	167
Accrued PBM fees	0	571
Other accrued liabilities	102	164
Total	$ 10,329	$ 12,158

Note 12 - Notes Payable (Detail

Note 12 - Notes Payable (Details Textual) - USD ($)		1 Months Ended					3 Months Ended		6 Months Ended
	Dec. 31, 2018	Sep. 30, 2022	Jul. 31, 2022	Sep. 30, 2021	Apr. 30, 2021	Jan. 31, 2019	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Notes Payable, Current							$ 142,000		$ 142,000		$ 145,000
Property, Plant and Equipment, Net							3,157,000		3,157,000		3,284,000
Interest Expense, Debt							14,000	$ 31,000	28,000	$ 82,000
Mortgage Note Payable Commercial Bank Collateralized [Member]
Secured Debt	$ 1,530,000
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Repayments of Debt						$ 11,901
Note Payable Collateralized Pharmacy Equipment [Member]
Debt Instrument, Interest Rate, Stated Percentage				6.90%
Payments to Acquire Machinery and Equipment					$ 30,000
Debt Instrument, Periodic Payment				$ 331
Notes Payable, Current							4,000		4,000		6,000
Note Payable Collateralized [Member] | Pharmacy Equipment [Member]
Debt Instrument, Interest Rate, Stated Percentage			8.78%
Payments to Acquire Machinery and Equipment			$ 90,000
Notes Payable, Current							66,000		66,000		74,000
Property, Plant and Equipment, Net							65,000		65,000		71,000
Note Payable Collateralized [Member] | Pharmacy Equipment [Member] | Sixty Monthly Payments [Member]
Debt Instrument, Periodic Payment			$ 1,859
Note Payable Collateralized [Member] | Vehicles [Member]
Debt Instrument, Interest Rate, Stated Percentage		8.29%
Payments to Acquire Machinery and Equipment		$ 25,000
Debt Instrument, Periodic Payment		$ 1,143
Property, Plant and Equipment, Net							16,000		16,000		18,000
Notes Payable							$ 3,000		$ 3,000		$ 10,000
Next Plat Investors [Member]
Debt Instrument, Maturity Date	Dec. 14, 2028

Note 12 - Notes Payable - Sched

Note 12 - Notes Payable - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Note payable	$ 1,194	$ 1,255
Less: current portion of notes payable	142	145
Long-term portion of notes payable	1,052	1,110
Mortgage Note Payable Commercial Bank Collateralized [Member]
Note payable	1,096	1,140
Note Payable Uncollateralized [Member]
Note payable	25	25
Note Payable Collateralized [Member]
Note payable	$ 73	$ 90

Note 12 - Notes Payable - Sch_2

Note 12 - Notes Payable - Schedule of Future Maturities (Details) $ in Thousands	Jun. 30, 2024 USD ($)
2024 (remaining six months)	$ 84
2025	114
2026	119
2027	124
2028	753
Total	$ 1,194

Note 13 - Stockholders' Equity

Note 13 - Stockholders' Equity (Details Textual) - USD ($)				1 Months Ended			6 Months Ended
	Jul. 01, 2023	May 09, 2023	May 05, 2023	Aug. 31, 2022	Aug. 30, 2022	Jul. 31, 2014	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Sep. 02, 2022
Preferred Stock, Shares Authorized (in shares)							10,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.0001		$ 0.0001
Payments of Stock Issuance Costs							$ 0	$ 120,000
Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 2.2
Debenture Purchase Agreement, Term (Year)			3 years
Debenture Purchase Agreement, Maximum Debt to be Issued			$ 10,000,000
Secured Debt			$ 0
Debt Conversion Agreement [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 2.2
Debt Conversion, Original Debt, Amount			$ 2,900,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)			1,312,379
Debt Conversion Agreement [Member] | NextPlat Corp. [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		570,599	570,599
Debt Conversion Agreement [Member] | Chairman and Chief Executive Officer [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		228,240	228,240
Debt Conversion Agreement [Member] | Vice-Chairman of the Board of Directors [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		228,240	228,240
Amended and Restated Secured Convertible Promissory Note [Member]
Debt Instrument, Face Amount										$ 2,800,000
PIPE Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 2.2
Warrants and Rights Outstanding, Term (Year)			3 years
Warrants and Rights Outstanding			$ 1,000,000
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	230,056
Conversion Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 2.2
Warrants and Rights Outstanding, Term (Year)			3 years
Warrants and Rights Outstanding			$ 2,700,000				600,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1	1
Class of Warrants or Rights, Exercised (in shares)	230,000
Stock Issued During Period, Value, Warrants Exercised	$ 506,000
Stock Issued During Period, Shares, Cash Exercise of Warrants (in shares)	230,000
Conversion Warrants [Member] | NextPlat Corp. [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	172,213
Class of Warrants or Rights, Exercised, Cashless (in shares)	340,599
Conversion Warrants [Member] | Messrs. Fernandez and Barreto [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	115,402
Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 2.2
Warrants and Rights Outstanding, Term (Year)			5 years
Warrants and Rights Outstanding			$ 200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			91,000
Inducement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 2.2
Warrants and Rights Outstanding, Term (Year)			3 years
Warrants and Rights Outstanding			$ 700,000				$ 200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			330,000
Inducement Warrants [Member] | Chairman and Chief Executive Officer [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		190,000	190,000
Inducement Warrants [Member] | Vice-Chairman of the Board of Directors [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		30,000	30,000
Inducement Warrants [Member] | Messrs. Fernandez [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	96,068
Inducement Warrants [Member] | Barreto [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	15,169
Securities Purchase Agreement [Member]
Proceeds From Issuance or Sale of Equity, Gross			$ 1,000,000
Equity Offering, Units Issued (in shares)			455,000
Equity Offering, Units Issued, Price Per Share (in dollars per share)			$ 2.2
Number of Shares Per Unit Issued (in shares)			1
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001
Number of Warrants Per Unit (in shares)			1
Proceeds from Issuance or Sale of Equity			$ 880,000
Payments of Stock Issuance Costs			70,000
Legal Fees			$ 50,000
Securities Purchase Agreement [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.0001
Sale of Stock, Number of Shares Issued in Transaction (in shares)					3,000
Proceeds from Issuance of Private Placement					$ 6,000,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)							51		51
Preferred Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.001		$ 0.001
Stock Issued During Period, Shares, New Issues (in shares)				51		51
Preferred Stock, Voting Percentage						50.99%
Amount for Exchange of Voting Power						$ 20,000
Stock Issued During Period, Shares, Acquisitions (in shares)				127,564
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)							100,000		100,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.0001		$ 0.0001
Undesignated Preferred Stock, Shares Authorized (in shares)							9,899,949		9,899,949
Undesignated Preferred Stock, Par Value (in dollars per share)							$ 0.0001		$ 0.0001
Preferred Stock, Liquidation Preference Per Share (in dollars per share)					$ 2,000
Series B Preferred Stock [Member] | Securities Purchase Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 2,000
Preferred Stock Voting Rights Shares (in shares)					500
Debt Instrument, Convertible, Conversion Price (in dollars per share)					$ 4
Proceeds From Issuance or Sale of Equity, Gross					$ 1,000,000

Note 14 - Stock-based Compens_2

Note 14 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expense	$ 65,000	$ 200,000	$ 0	$ 300,000
Share-Based Payment Arrangement, Expense, Tax Benefit			$ 0

Note 15 - Reportable Segments_2

Note 15 - Reportable Segments (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Number of Reportable Segments			2
Pharmacy Operations [Member]
Segment, Expenditure, Addition to Long-Lived Assets	$ 18,000	$ 200,000	$ 100,000	$ 200,000

Note 15 - Reportable Segments -

Note 15 - Reportable Segments - Summary of Reportable Segments (Details) - USD ($) $ in Thousands		3 Months Ended					6 Months Ended
		Jun. 30, 2024		Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024		Jun. 30, 2023
Revenues, net		$ 13,477			$ 11,556		$ 28,105		$ 22,948
Costs of revenue		8,782			7,997		19,405		16,242
Gross profit		4,695			3,559		8,700		6,706
Salaries and wages		2,166			1,701		4,282		3,300
Professional fees		384			274		862		1,048
Depreciation and amortization		757			72		1,533		137
Selling, general, and administrative		895			888		1,795		1,583
Impairment loss		9,792	[1]		0		9,924	[1]	0
Total operating expenses		13,994			2,935		18,396		6,068
Loss from operations		(9,299)			624		(9,696)		638
Other (expense) income		23			(5,261)		48		(5,405)
Loss before income taxes		(9,276)			(4,637)		(9,648)		(4,767)
Provision for income taxes		0			0		0		0
Net loss		(9,276)		$ (372)	(4,637)	$ (130)	(9,648)		(4,767)
Intersegment Eliminations [Member]
Revenues, net		0			0		0		0
Costs of revenue		0			0		0		0
Gross profit		0			0		0		0
Salaries and wages		174			154		356		276
Professional fees		314			208		707		503
Depreciation and amortization		4			5		9		5
Selling, general, and administrative		143			246		266		349
Impairment loss	[1]	0					0
Total operating expenses		635			613		1,338		1,133
Loss from operations		(635)			(613)		(1,338)		(1,133)
Other (expense) income		38			(5,246)		78		(5,378)
Loss before income taxes		(597)			(5,859)		(1,260)		(6,511)
Provision for income taxes		0			0		0		0
Net loss		(597)			(5,859)		(1,260)		(6,511)
Product [Member]
Revenues, net		10,518			9,399		21,773		19,193
Costs of revenue		8,719			7,937		19,279		16,132
Product [Member] | Intersegment Eliminations [Member]
Revenues, net		0			0		0		0
Costs of revenue		0			0		0		0
Service [Member]
Revenues, net		2,959			2,157		6,332		3,755
Costs of revenue		63			60		126		110
Service [Member] | Intersegment Eliminations [Member]
Revenues, net		0			0		0		0
Costs of revenue		0			0		0		0
Pharmacy Operations [Member] | Operating Segments [Member]
Revenues, net		13,167			10,876		27,262		21,751
Costs of revenue		8,719			7,937		19,279		16,132
Gross profit		4,448			2,939		7,983		5,619
Salaries and wages		1,958			1,527		3,859		2,972
Professional fees		25			6		29		389
Depreciation and amortization		604			63		1,219		123
Selling, general, and administrative		747			638		1,517		1,226
Impairment loss	[1]	6,595					6,727
Total operating expenses		9,929			2,234		13,351		4,710
Loss from operations		(5,481)			705		(5,368)		909
Other (expense) income		(15)			(15)		(30)		(27)
Loss before income taxes		(5,496)			690		(5,398)		882
Provision for income taxes		0			0		0		0
Net loss		(5,496)			690		(5,398)		882
Pharmacy Operations [Member] | Product [Member] | Operating Segments [Member]
Revenues, net		10,518			9,399		21,773		19,193
Costs of revenue		8,719			7,937		19,279		16,132
Pharmacy Operations [Member] | Service [Member] | Operating Segments [Member]
Revenues, net		2,649			1,477		5,489		2,558
Costs of revenue		0			0		0		0
Third-party Administration [Member] | Operating Segments [Member]
Revenues, net		310			680		843		1,197
Costs of revenue		63			60		126		110
Gross profit		247			620		717		1,087
Salaries and wages		34			20		67		52
Professional fees		45			60		126		156
Depreciation and amortization		149			4		305		9
Selling, general, and administrative		5			4		12		8
Impairment loss	[1]	3,197					3,197
Total operating expenses		3,430			88		3,707		225
Loss from operations		(3,183)			532		(2,990)		862
Other (expense) income		0			0		0		0
Loss before income taxes		(3,183)			532		(2,990)		862
Provision for income taxes		0			0		0		0
Net loss		(3,183)			532		(2,990)		862
Third-party Administration [Member] | Product [Member] | Operating Segments [Member]
Revenues, net		0			0		0		0
Costs of revenue		0			0		0		0
Third-party Administration [Member] | Service [Member] | Operating Segments [Member]
Revenues, net		310			680		843		1,197
Costs of revenue		$ 63			$ 60		$ 126		$ 110
[1]Pharmacy Operations impairment loss during the six months ended June 30, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.

Note 15 - Reportable Segments_3

Note 15 - Reportable Segments - Total Assets (Details) - USD ($) $ in Thousands		Jun. 30, 2024	Dec. 31, 2023
Total Assets		$ 28,827	$ 40,384
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Total Assets		0	69
Intersegment Eliminations [Member]
Total Assets	[1]	(2,774)	(2,774)
Pharmacy Operations [Member] | Operating Segments [Member]
Total Assets		29,900	38,516
Third-party Administration [Member] | Operating Segments [Member]
Total Assets		$ 1,701	$ 4,573
[1]Eliminations consist of investments in subsidiaries between the Pharmacy Operations segment and Corporate.

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Details Textual) - USD ($)					3 Months Ended	6 Months Ended
	May 09, 2023	May 05, 2023	May 01, 2023	Feb. 01, 2023	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023
Common Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.0001	$ 0.0001	$ 0.0001
Inducement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		330,000
Conversion Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1	1
Chairman and Chief Executive Officer [Member] | Inducement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	190,000	190,000
Vice-Chairman of the Board of Directors [Member] | Inducement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	30,000	30,000
Debt Conversion Agreement [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		1,312,379
Debt Conversion Agreement [Member] | NextPlat Corp. [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	570,599	570,599
Debt Conversion Agreement [Member] | Chairman and Chief Executive Officer [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	228,240	228,240
Debt Conversion Agreement [Member] | Vice-Chairman of the Board of Directors [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	228,240	228,240
Securities Purchase Agreement [Member]
Equity Offering, Units Issued (in shares)		455,000
Equity Offering, Units Issued, Price Per Share (in dollars per share)		$ 2.2
Proceeds From Issuance or Sale of Equity, Gross		$ 1,000,000
Number of Shares Per Unit Issued (in shares)		1
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001
Number of Warrants Per Unit (in shares)		1
Management Services Agreement [Member] | NextPlat Corp. [Member]
Payment for Management Fee					$ 60,000	$ 120,000
Management Fee Expense			$ 20,000	$ 25,000	$ 65,000	$ 115,000